海吉亞醫療(6078.HK)連續第4日上漲 股價創3個月新高
格隆匯5月18日丨中國最大的腫瘤醫療集團海吉亞醫療(6078.HK)近日持續上漲,今日盤中再度漲超7%報72.35港元,股價創3個月新高,連漲4日,累漲約20%,最新市值438億港元。公司4月底曾宣佈計劃以17.346億元人民幣收購蘇州永鼎醫院98%的股權。投行普遍認為此次收購有望加速集團蘇州地區增長,中金給予76.8港元目標價,麥格理將目標價調升至76.21港元;中泰證券維持買入評級,認為公司未來有望通過自建+併購逐步覆蓋全國。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.